Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026
Perspective Therapeutics announced that data from its [²¹²Pb]VMT01 melanoma program were accepted for poster presentation at the SITC 41st Annual Meeting, November 4-8, 2026, in Phoenix. The Phase I/IIa MC1R-targeted alpha-particle trial combines VMT01 with nivolumab; prior interim data (March 25, 2026 cutoff) showed 2 of 7 responders in the 3.0 mCi cohort with 86% achieving stable disease or partial response. The asset was well tolerated with no dose-limiting toxicities and no Grade 4/5 events.
Key figures
- Drug Name
- lapemelanotide zapixetar ([²¹²Pb]VMT01)
- Phase Of Trial
- Phase I/IIa
- Responders
- 2 of 7 patients in 3.0 mCi monotherapy cohort
- Data cutoff
- March 25, 2026
- Grade3 teae rate
- 8 of 27 patients (30%)
- Stable disease or pr
- 6 of 7 patients (86%) in 3.0 mCi cohort
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.